BTK promotes neuroinflammation by interacting with hub genes and modulating microglia following intracerebral hemorrhage

This study demonstrates that Bruton's tyrosine kinase (BTK) exacerbates neuroinflammation following intracerebral hemorrhage by acting as a hub gene that modulates microglial immune pathways, polarization toward pro-inflammatory states, and intercellular communication, thereby suggesting that BTK inhibition alleviates neurological deficits.

The Gist

The Big Picture: A Brain Bleed and the "Overzealous Firefighter"

Imagine your brain is a bustling city. When a cerebral hemorrhage (ICH) happens, it's like a major pipe bursting, flooding a neighborhood with blood. This is the "primary injury." But the real trouble starts afterward. The floodwater (blood) breaks down and releases toxic chemicals, triggering a massive, chaotic response from the city's emergency services.

In the brain, these emergency services are microglia (the brain's immune cells). Normally, they are helpful janitors and repair crews. But after a bleed, they often go into "panic mode." They start screaming, throwing things, and causing more damage than the original leak. This is neuroinflammation.

This paper asks a simple question: Is there a specific "alarm button" that keeps these emergency crews in panic mode?

The researchers found that button. It's called BTK (Bruton's Tyrosine Kinase). They discovered that BTK is like the super-bright siren on a fire truck. When BTK is turned on, the microglia go crazy, attacking the brain tissue and preventing it from healing.

The Experiment: Turning Down the Siren

The researchers used mice to simulate a brain bleed. Then, they gave one group of mice a drug called Ibrutinib. Think of Ibrutinib as a mute button for that BTK siren.

The Results:

• Without the mute button: The mice's brains were flooded with inflammation. The "emergency crews" (microglia) were aggressive, causing more damage. The mice had trouble moving and were very sick.
• With the mute button: The inflammation calmed down. The emergency crews stopped attacking and started behaving more like repair crews. The mice moved better and recovered faster.

The Detective Work: Finding the "Hub"

The researchers didn't just stop at "it works." They wanted to know how. They used advanced computer tools (like a giant digital map of gene activity) to find the connections.

1. The Hub Gene: They found that BTK is a "hub." Imagine a busy airport control tower. BTK is the tower. If the tower is screaming, every plane (gene) in the system changes its flight path. They found 12 other "planes" (genes) that are tightly connected to BTK's tower, all involved in the chaos of inflammation.
2. The Main Suspects: They zoomed in on the microglia. They realized that microglia are the ones holding the BTK siren the loudest. In fact, microglia were responsible for about 76% to 83% of all the BTK activity in the brain after a bleed.

The "Personality" Shift: From Repair Crew to Riot Squad

The study looked closely at the microglia and found something fascinating about their "personalities."

• The "Bad" Microglia (High BTK): When BTK was loud, the microglia turned into Riot Squads (M1/M2b type). They were aggressive, releasing toxic chemicals, and shouting at other immune cells to join the fight. They were great at causing damage but bad at cleaning up.
• The "Good" Microglia (Low BTK): When the researchers silenced BTK, the microglia shifted into Repair Crews (M2 type). They stopped shouting, started cleaning up the debris, and sent out signals to help the brain heal.

The Chain Reaction: A Social Network of Inflammation

Finally, the researchers looked at how these cells talk to each other. They used a tool called "CellChat" (think of it as listening in on a group chat).

They found that when BTK is active, the microglia are spamming the group chat. They are sending aggressive messages (signals) to every other immune cell in the brain, telling them to come over and cause trouble.
When they silenced BTK, the spam stopped. The microglia stopped calling the other cells to join the riot, and the whole neighborhood calmed down.

The Takeaway: Why This Matters

This paper is like finding the master switch for a brain's inflammatory overreaction.

• The Problem: After a brain bleed, the brain's immune system often hurts the patient more than the bleed itself.
• The Solution: The drug Ibrutinib (which is already used to treat some blood cancers) can turn off the BTK siren.
• The Future: By turning off BTK, we can stop the "Riot Squad" microglia and encourage the "Repair Crew" microglia. This could mean less brain damage, better recovery, and fewer disabilities for people who suffer from brain bleeds.

In short: The researchers found the "volume knob" for brain inflammation. Turning it down with a specific drug helps the brain heal itself instead of fighting itself.

Technical Summary

Title

BTK promotes neuroinflammation by interacting with hub genes and modulating microglia following intracerebral hemorrhage.

1. Problem Statement

Intracerebral hemorrhage (ICH) is a devastating stroke subtype with high mortality and disability rates. While primary brain injury results from mechanical damage, secondary brain injury is driven largely by neuroinflammation, triggered by erythrocyte lysis, iron toxicity, and the activation of immune cells (particularly microglia). Although Bruton's tyrosine kinase (BTK) is known to regulate inflammation in B cells and myeloid cells, and BTK inhibitors (e.g., ibrutinib) are used in oncology and autoimmune diseases, the specific role and molecular mechanisms of BTK in ICH-induced neuroinflammation remain poorly understood. There is a critical need to elucidate how BTK influences microglial behavior and neuroinflammatory pathways to develop targeted therapeutic strategies.

2. Methodology

The study employed a multi-omics approach combining in vivo animal models with in silico transcriptomic analyses:

• Animal Model: A mouse ICH model was established via collagenase injection into the right basal ganglia of C57BL/6N mice.
• Pharmacological Intervention: Mice were treated with ibrutinib (a BTK inhibitor) at varying doses (3, 6, 9 mg/kg) to determine the optimal dose (6 mg/kg selected). Treatment began 30 minutes post-ICH and continued daily.
• Behavioral Assessment: Neurological function was evaluated using four tests: Corner turn, Forelimb placing, Cylinder, and Wire hanging tests over 14 days.
• Molecular Analysis:
  • Western Blotting: Quantified protein levels of BTK, inflammatory cytokines (IL-6, IL-1β, TNF-α), anti-inflammatory markers (Arg-1), phagocytic receptors (CD68, CD11b), and signaling molecules (NLRP3, TLR4) at 1, 3, and 7 days post-ICH.
  • Bulk RNA-seq Analysis: Utilized the GSE206971 dataset (ICH vs. Sham at day 3). Differentially expressed genes (DEGs) were identified, followed by Weighted Gene Co-expression Network Analysis (WGCNA) to find gene modules correlated with ICH. Protein-Protein Interaction (PPI) networks were constructed to identify hub genes interacting with Btk.
  • Single-Cell RNA-seq (scRNA-seq) Analysis: Utilized the GSE230414 dataset (CD45+ immune cells from ICH vs. Sham). Cells were clustered and annotated. Microglia were stratified into BTK_high and BTK_low subgroups based on expression levels.
  • Functional Enrichment: Gene Ontology (GO), KEGG, Gene Set Enrichment Analysis (GSEA), and Gene Set Variation Analysis (GSVA) were performed to characterize pathways.
  • Cell-Cell Communication: The CellChat package was used to infer ligand-receptor interactions between microglia and other immune cells.

3. Key Contributions

• Mechanistic Insight: First study to comprehensively map the role of BTK in ICH-induced neuroinflammation, linking it to specific hub genes and microglial polarization.
• Hub Gene Identification: Identified a regulatory network of 12 BTK-related hub genes (including Adgre1, S100a10, Emp1, Il10rb, S100a13, Gm13167, Kif22, Sgpl1, Gm7665, Plxnb2, Birc5, Gas2l3) that interact closely with Btk and are critical for the inflammatory response.
• Microglial Stratification: Demonstrated that microglia are the primary immune cells expressing BTK in the ICH brain and that high BTK expression drives a pro-inflammatory phenotype.
• Therapeutic Validation: Provided preclinical evidence that inhibiting BTK with ibrutinib significantly improves neurological outcomes and reduces neuroinflammation.

4. Key Results

A. BTK Expression and Pharmacological Effects

• Temporal Dynamics: BTK expression (both mRNA and protein) significantly increased after ICH, peaking at 3 days and returning to baseline by 28 days.
• Neuroprotection: Ibrutinib treatment (6 mg/kg) significantly improved neurological scores in all behavioral tests (Corner turn, Forelimb placing, Cylinder, Wire hanging) at days 1, 2, 7, and 14 post-ICH compared to vehicle controls.
• Anti-inflammatory Effect: Ibrutinib reduced pro-inflammatory cytokines (IL-6, IL-1β, TNF-α) and NLRP3/TLR4 signaling while increasing the anti-inflammatory marker Arg-1. It also modulated phagocytic receptors (decreased CD68 at day 1, increased CD11b at day 3).

B. Transcriptomic Network Analysis

• WGCNA: Btk was identified as a hub gene within the "green dynamic" module, which showed the highest correlation with the ICH phenotype.
• Hub Genes: PPI analysis revealed 12 genes closely interacting with Btk. These genes are involved in immune processes, signal transduction, cell migration, and mitosis. GO analysis of the associated cluster suggested a role in cell mitosis, implying BTK may regulate immune cell proliferation.

C. Single-Cell Analysis of Microglia

• Cellular Source: Microglia expressed the highest proportion of BTK (76.4% in Sham, 83.7% in ICH) among all CD45+ immune cells.
• BTK_high vs. BTK_low Microglia:
  • Pathway Enrichment: BTK_high microglia showed upregulation of pro-inflammatory pathways (innate/adaptive immunity, NF-κB, TNF, inflammasome assembly) and downregulation of anti-inflammatory/repair pathways (TGF-β, M-CSF, PPAR, phagolysosome fusion).
  • Polarization: BTK_high microglia exhibited a strong shift toward M1 (pro-inflammatory) and M2b phenotypes. Conversely, BTK_low microglia tended toward M2a/M2c (anti-inflammatory/repair) and homeostatic states.
  • Intercellular Communication: BTK_high microglia demonstrated significantly stronger communication with other immune cells via inflammatory pathways (IL-1, IL-2, CXCL, IFN-I, TNF, CCL, CSF) compared to BTK_low microglia.

5. Significance and Conclusion

• Therapeutic Potential: The study validates ibrutinib as a promising therapeutic candidate for early brain injury following ICH by suppressing neuroinflammation.
• Mechanistic Clarity: It establishes that BTK drives neuroinflammation by:
  1. Interacting with a specific network of 12 hub genes.
  2. Promoting microglial polarization toward pro-inflammatory (M1/M2b) states.
  3. Enhancing intercellular communication that amplifies the inflammatory cascade.
• Future Directions: While the study focuses on CD45+ immune cells, the authors acknowledge the need to investigate BTK's role in non-immune cells (e.g., astrocytes) and validate the identified hub genes experimentally.

Conclusion: Targeting BTK modulates the neuroinflammatory microenvironment post-ICH, shifting microglia from a destructive to a reparative state, thereby offering a novel strategy to improve clinical outcomes in hemorrhagic stroke.